Tvardi Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies targeting STAT3 for fibrosis-driven diseases, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025. The company's management will also host investor one-on-one meetings during the conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251104976579) on November 04, 2025, and is solely responsible for the information contained therein.